Outcomes of Arthroscopic Anterior Cruciate Ligament Reconstruction with Versus Without Platelet-Rich Plasma Augmentation: A Prospective Randomized Controlled Trial
International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)
DOI: 10.25258/ijcpr.18.5.268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Sikandar Rajak und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Anterior cruciate ligament (ACL) reconstruction is among the most frequently performed orthopaedic procedures, yet the early rehabilitation phase remains challenged by graft healing and postoperative pain. Platelet-rich plasma (PRP), a concentrated autologous source of growth factors, has emerged as a potential biological adjunct to accelerate soft-tissue healing and improve functional outcomes following ACL reconstruction.
Aim
To compare functional outcomes, pain scores, return-to-sport rates, and complication profiles of arthroscopic ACL reconstruction performed with versus without intra-operative PRP augmentation at a tertiary teaching hospital.
Methods
This prospective, parallel-group, randomized controlled trial enrolled 85 patients undergoing primary arthroscopic ACL reconstruction at Jawaharlal Nehru Medical College and Hospital, Bhagalpur, Bihar, India, between December 2023 and November 2025. Patients were randomized into the PRP group (n=43) and the control group (n=42). The primary outcomes were the Lysholm Knee Score and the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form assessed at baseline, 3, 6, and 12 months. Secondary outcomes included the Visual Analogue Scale (VAS) for pain, knee flexion range of motion, graft integration on MRI, return-to-sport (RTS) rates, and complication profiles.
Results
At 12 months, the PRP group demonstrated significantly superior Lysholm scores (91.4 ± 4.2 vs 85.3 ± 5.1; p < 0.001), IKDC scores (78.9 ± 4.6 vs 71.2 ± 5.3; p < 0.001), and lower VAS pain scores (1.2 ± 0.6 vs 1.8 ± 0.7; p < 0.001) compared to controls. RTS at 12 months was significantly higher in the PRP group (90.7% vs 71.4%; p = 0.018), and mean time to RTS was shorter (8.2 ± 1.4 vs 9.6 ± 1.8 months; p < 0.001). Total complication rates were lower in the PRP group (11.6% vs 23.8%), though this did not reach statistical significance (p = 0.132).
Conclusion
Intra-operative PRP augmentation during arthroscopic ACL reconstruction significantly improves functional outcomes, accelerates pain resolution, and facilitates earlier return to sport at 12-month follow-up. PRP augmentation represents a safe, effective, and safe and effective biological adjunct that may be considered as a useful adjunct in selected ACL reconstruction cases, particularly in active and athletic populations.
Zitieren
APA
Rajak, S., Ranjan, P., Lal, M., & Raj, S. (2026). Outcomes of Arthroscopic Anterior Cruciate Ligament Reconstruction with Versus Without Platelet-Rich Plasma Augmentation: A Prospective Randomized Controlled Trial. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.268
Vancouver
Rajak S, Ranjan P, Lal M, Raj S. Outcomes of Arthroscopic Anterior Cruciate Ligament Reconstruction with Versus Without Platelet-Rich Plasma Augmentation: A Prospective Randomized Controlled Trial. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.268
BibTeX
@article{Rajak2026,
author = {Rajak, Sikandar and Ranjan, Parbhat and Lal, Makhan and Raj, Shubham},
title = {Outcomes of Arthroscopic Anterior Cruciate Ligament Reconstruction with Versus Without Platelet-Rich Plasma Augmentation: A Prospective Randomized Controlled Trial},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {05},
doi = {10.25258/ijcpr.18.5.268}
}
EUVIMED